NanoViricides, Inc. (NYSE American: NNVC) has announced that a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo (DRC). Site preparation and staff training are scheduled for early April 2026, following regulatory approval from the DRC agency. The study will evaluate the safety and effectiveness of NV-387 against Clade I MPox, a more severe strain responsible for the ongoing outbreak in the region.
This trial is pivotal as MPox continues to pose a global health threat, particularly in Africa where healthcare infrastructure is limited. The DRC has experienced a significant surge in MPox cases, with Clade I having a higher mortality rate compared to the Clade II strain that caused the 2022 global outbreak. NV-387, a broad-spectrum antiviral, is designed to target multiple viruses, including orthopoxviruses. The company is also seeking Orphan Drug Designation from the U.S. FDA, which could accelerate development and provide market exclusivity.
The initiation of this trial underscores NanoViricides' commitment to advancing its pipeline. NV-387 has already shown promise in preclinical studies against various viral infections, including COVID-19 and influenza. The company believes that its nanoviricide technology, which uses polymeric micelles to deliver drugs directly to viruses, offers a novel approach to antiviral therapy. If successful, NV-387 could become a critical treatment for MPox, especially given the limited therapeutic options currently available.
Investors should note that drug development is inherently risky, and there is no guarantee that NV-387 will prove safe and effective in clinical trials. However, the company's progress in securing regulatory approval and initiating the trial in the DRC represents a significant milestone. For more details, the full press release is available at https://ibn.fm/4Ckhk. Updates on NNVC can be found in the company’s newsroom at https://ibn.fm/NNVC.
NanoViricides is a clinical-stage company focusing on developing nanomaterials for antiviral therapy. Its lead candidate, NV-387, is being developed for respiratory viral infections and MPox. The company’s technology is licensed from TheraCour Pharma, Inc. As with any pharmaceutical development, the path to approval is lengthy and capital-intensive, and there can be no assurance of success.
